# TROPION-Urothelial04 (NCT07720284)

> An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07720284
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: High-risk Muscle Invasive Urothelial Carcinoma
- Interventions: Dato-DXd; Rilvegostomig; Durvalumab; Nivolumab; Pembrolizumab; Enfortumab vedotin
- Enrollment: 915
- Primary outcome: To demonstrate the superiority of Dato-DXd + rilvegostomig (Arm 1) relative to SoC (Arm 3) by assessment of disease-free survival (DFS) (based on Investigator assessments).

## Indexed commentary on TROPION-Urothelial04 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tropion-urothelial04-nct07720284